MLKL and cancer: For instance, a variety of cancers displayed low/loss expression of RIP3/MLKL and necroptotic resistance [12, 13, 54], while others including pancreatic cancer [55], colorectal cancer [56] and head and neck caner [24] showed high necroptotic rates [12, 13].